AI Embryologist: The Future of Fertility Jobs
▼ Summary
– Fairtility’s CHLOE is an FDA-approved AI tool that analyzes embryo viability using millions of data points to identify those with the highest implantation potential.
– Current IVF embryo screening involves costly and time-consuming genetic testing that only checks for correct chromosome count, not overall embryo health.
– CHLOE continuously assesses embryos against optimal development characteristics, producing an AI score to evaluate their growth and implantation readiness.
– AI is expected to automate embryo assessments, reducing the need for biopsies and allowing embryologists to focus more on scientific analysis.
– The technology acts as a virtual lab assistant, streamlining embryo selection and enabling the study of development data that was previously inaccessible.
The integration of artificial intelligence into embryology is reshaping fertility treatments, offering new hope to countless individuals and couples. At the forefront of this transformation is Fairtility, where Chief Scientific Officer Wiemer leads clinical efforts. The company utilizes a sophisticated AI algorithm named CHLOE, an acronym for Cultivating Human Life through Optimal Embryos. This system has been trained on millions of data points from embryos and their subsequent outcomes. Its primary function involves rapidly analyzing a patient’s embryos to identify those with the greatest likelihood of successful implantation. According to the company, this capability can significantly improve the time it takes to achieve pregnancy and increase live birth rates. While its effectiveness has so far been validated through retrospective studies, CHLOE holds the distinction of being the first and only FDA-approved AI tool for embryo assessment.
A significant challenge in traditional IVF is the process of creating genetically normal embryos. Embryologists must perform a biopsy, collecting cells from each embryo to be sent for external genetic testing. This step alone can add thousands of dollars to the overall cost and delay results for up to two weeks. Furthermore, a successful genetic screen only confirms that an embryo has the correct number of chromosomes, which does not provide a complete picture of its overall health and viability.
Wiemer explains that an embryo’s core function is to divide. He notes that there are millions of critical data points related to this process, including the characteristics of cell division, the area and size of the inner cell mass, and the frequency of contractions in the trophectoderm, the layer that forms the future placenta. The AI model continuously evaluates a group of embryos against these optimal developmental characteristics at every stage. CHLOE essentially answers two fundamental questions: How well did the embryo develop, and does it possess all the necessary components for a healthy implantation? The system culminates its analysis by producing a comprehensive AI score for each embryo.
Looking ahead, Wiemer envisions a future where reducing the transfer of abnormal embryos won’t require an invasive biopsy. He predicts that automatic assessments of embryo development will become a standard practice in every embryology laboratory.
The field of embryology itself is undergoing a profound change. Wiemer, who began his career in animal science, observes that the main difference in human embryology is the immense amount of administrative work. He estimates that embryologists currently spend about forty percent of their time on tasks unrelated to their scientific expertise. He believes AI will declutter the profession, allowing embryologists to return to their primary role as scientists. This shift means more time can be dedicated to studying embryos, confirming normal development, and leveraging new insights to improve embryo selection for transfer.
Wiemer describes CHLOE as a virtual lab assistant that aids in embryo selection, monitors optimal conditions, and generates reports for patients and clinical staff. He finds it incredibly rewarding to now have the capability to study vast amounts of data and understand the factors that influence embryo development, a feat that was nearly impossible just a few years ago.
(Source: Technology Review)
